Wednesday, June 10, 2026

pharma

Celgene Europe

Celgene Europe patent portfolio β€” 13 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

EU HQ
EMA registrant Type
Company details
Status
Public
HQ
EU
Programs
0
Drugs
0
Patents
13
Intelligence Β· Patents

Celgene Europe patents

13 pharmaceutical patents indexed for Celgene Europe. 0 expire within 24 months.

Celgene Europe has 13 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months β€” use filters for patent-cliff planning.

Patent portfolio

  1. EP 3539539

    TABLETTENFORMULIERUNGEN AUS (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLIN-1,3-DION

    Expires Tue Sep 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. EP 3320902

    VERFAHREN ZUR BEHANDLUNG VON ERKRANKUNGEN MIT ISOINDOLINVERBINDUNGEN

    Expires Tue May 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. MX 2015008685

    TREATMENT OF PSORIATIC ARTHRITIS USING APREMILAST.

    Expires Sun Sep 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. AU 2012362562

    Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione

    Expires Wed Jul 12 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. AU 2012308663

    Formulations of cyclopropanecarboxylic acid {2-[1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware

    Expires Wed Mar 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. AU 2012249536

    Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases

    Expires Wed Nov 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. EP 2651400

    ORALE RETARD-DARREICHUNGSFORMEN VON SCHWER LΓ–SLICHEN ARZNEIMITTELN UND IHRE VERWENDUNG

    Expires Tue Oct 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. AU 2013203283

    Processes for the preparation of (S)-1-(3-ethoxy-4-methoxyophenyl)-2-methanesulfonylethylamine

    Expires Wed Aug 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. AU 2012205809

    Phenethylsulfone isoindoline derivatives as inhibitors of PDE 4 and/or cytokines

    Expires Wed Apr 27 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. EP 2555769

    VERFAHREN ZUR BEHANDLUNG VON VIRALEN ATEMWEGSINFEKTIONEN

    Expires Tue Feb 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. AU 2008353468

    Solid forms comprising (+)-2- [1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl] -4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof

    Expires Wed Sep 26 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. AU 2005269367

    Isoindoline compounds and methods of their use

    Expires Wed Feb 04 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired
  13. AU 2003224729

    (+)-2-(1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL)-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF

    Expires Tue Oct 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

How many patents does Celgene Europe have?

13 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Celgene Europe patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.